HIBT Lab! Immunai: Noam Solomon
Noam Solomon, co-founder and CEO of Immunai, explains how his company is using artificial intelligence and single-cell data to create an atlas of the human immune system. Solomon describes the challenge of bridging the gap between animal models and human immune responses to improve drug development efficiency. He details how Immunai partners with pharmaceutical companies to analyze clinical trial data, helping to identify effective therapies and predict patient outcomes for diseases like cancer.